The earnings call presented a balanced view with notable achievements in contact lens growth, dry eye treatments, and increased revenue guidance, but also faced challenges from the enVista recall and U.S. Generics decline. The sentiment is neutral as highlights and lowlights are balanced.

Company Guidance

During Bausch + Lomb's second quarter 2025 earnings call, the company highlighted several key metrics and provided updated financial guidance. The company reported a total revenue of $1.278 billion, reflecting a year-over-year growth of 3%, with Vision Care revenue up by 6% to $753 million and the Surgical segment growing by 1% to $216 million, despite a $29 million impact from the enVista recall. Excluding this recall, the Surgical segment would have grown by 15%. The Pharmaceutical segment saw a decline of 1%, attributed to underperformance in the U.S. generic business, which declined by 29%. Adjusted gross margin was reported at 60.6%, a 130 basis point decrease from the previous year. The company raised its full-year revenue guidance to a range of $5.05 billion to $5.15 billion, representing constant currency growth of 5% to 7%, and increased its adjusted EBITDA guidance to between $860 million and $910 million. The company emphasized a strong focus on execution, demonstrating resilience against unexpected challenges, and outlined plans for continued innovation and strategic growth, with a commitment to operational excellence and market expansion.

Strong Contact Lens Growth

Contact lens revenue growth was 7%, with the Daily SiHy franchise growing by 36% in Q2. The U.S. market saw 11% growth, EMEA 11%, LatAm 25%, Japan 3%, and China 7%.

Dry Eye Portfolio Success

Dry eye portfolio delivered $115 million in revenue in Q2, representing 19% growth. ARTELAC grew by 34% and Blink by 13%.

Prescription Dry Eye Leadership

MIEBO delivered $63 million of revenue in Q2, representing sequential growth of 11% and year-over-year growth of 50%. XIIDRA delivered $82 million in revenue with 12% year-over-year prescription growth.

Increased Revenue Guidance

Revenue guidance for 2025 has been raised to a range of $5.05 billion to $5.15 billion, reflecting constant currency growth of approximately 5% to 7%.

Successful Debt Refinancing

Completed a refinancing of $3.1 billion of debt, extending maturities to 2031 with minimal impact on interest expense.

Bausch + Lomb Corporation (BLCO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BLCO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.16 / -	0.17	―	―	―
Jul 30, 2025	2025 (Q2)	0.06 / 0.07	0.13	-46.15% (-0.06)
Apr 30, 2025	2025 (Q1)	0.02 / -0.07	0.07	-200.00% (-0.14)
Feb 19, 2025	2024 (Q4)	0.23 / 0.25	0.24	4.17% (+0.01)
Oct 30, 2024	2024 (Q3)	0.16 / 0.17	0.22	-22.73% (-0.05)
Jul 31, 2024	2024 (Q2)	0.13 / 0.13	0.18	-27.78% (-0.05)
May 01, 2024	2024 (Q1)	0.07 / 0.07	0.1	-30.00% (-0.03)
Feb 21, 2024	2023 (Q4)	0.17 / 0.24	0.23	4.35% (<+0.01)
Nov 01, 2023	2023 (Q3)	0.19 / 0.22	0.31	-29.03% (-0.09)
Aug 02, 2023	2023 (Q2)	0.15 / 0.18	0.29	-37.93% (-0.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BLCO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$14.65	$13.71	-6.42%
Apr 30, 2025	$13.72	$11.56	-15.74%
Feb 19, 2025	$16.35	$16.30	-0.31%
Oct 30, 2024	$20.76	$20.44	-1.54%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.